Galena Biopharma
Galena was the company behind NeuVax, a HER2 peptide vaccine meant to stop early breast cancer returning; the phase 3 PRESENT trial was stopped for futility in 2016 and Galena merged into SELLAS.
Overview
Galena Biopharma, founded in 2006 and headquartered in Portland, Oregon, developed nelipepimut-S (NeuVax), a HER2-derived E75 peptide vaccine given with GM-CSF to prevent recurrence in node-positive, HER2 low-expressing breast cancer. The phase 3 PRESENT trial was halted for futility in 2016; Galena merged with SELLAS Life Sciences in 2017. Its trials remain on ClinicalTrials.gov under Galena as lead sponsor.
Similar pages
not linked directly; found by shared links- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyGrifols
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyIntra-IMMUSG
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.